1242P - Progression of leptomeningeal metastases in advanced EGFR-mutated non-small cell lung cancer

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Non-Small Cell Lung Cancer
Presenter Qian Zhao
Citation Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383
Authors Q. Zhao1, L. Deng2, Y. Zhang3, X. Zhou3, Y. Li3, M. Yu3, L. Zhou3, B. Zou3, Y. Liu3, Y. Lu3
  • 1West China School Of Medicine, West China Hospital, Huaxi, Sichuan University, 610041 - Chengdu/CN
  • 2Department Of Thoracic Oncology, Cancer Center And State Key Laboratory Of Biotherapy, West China Hospital, Huaxi, Sichuan University, Chengdu/CN
  • 3Department Of Thoracic Oncology, Cancer Center And State Key Laboratory Of Biotherapy, West China Hospital, Huaxi, Sichuan University, 610041 - Chengdu/CN

Abstract

Background

Leptomeningeal metastasis (LM) has become increasingly common in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), but data are incomplete with respect to clinical features and treatment outcomes of LM in this population.

Methods

We retrospectively evaluated 420 advanced NSCLC patients effectively treated with EGFR-TKI. We studied LM progression of those patients, defining this as newly developed leptomeningeal metastases after a response to EGFR-TKI with or without pre-existing brain parenchyma lesions.

Results

Among 420 patients, LM occurred in 29 (6.9 %). Patients with EGFR L858R mutations were more likely to experience LM than those with exon 19 deletions (P = 0.006). The median time to LM progression was 16.5 months (95% CI, 11.9-20.8). The prognosis for LM patients was poor and the median survival was 5.2 months (95% CI, 3.2-7.2) after LM diagnosis. Patients who received BSC are significantly shorter than those with anti- tumor treatment (1.9m vs 6.0m, P 2 (14.2m vs 2.3m, P 

Conclusions

For advanced EGFR-mutated NSCLC patients who were effectively treated with EGFR-TKI, L858R mutation might be associated with higher risk of LM progression compared with exon 19 deletion. Performance status was an important prognostic factor. WBRT was a rational choice of the appropriate therapy and can improve the outcomes after LM progression.

Clinical trial identification

None

Legal entity responsible for the study

Yongmei Liu

Funding

National Natural Science Foundation of China (No. 81472196)

Disclosure

All authors have declared no conflicts of interest.